Tag: biosimilars
Immunogenicity in Biosimilars: Understanding Immune Response Differences
Explore why immunogenicity may differ in biosimilars compared to reference biologics. Learn about anti-drug antibodies, manufacturing impacts, and clinical safety data.
Future Biosimilars: Upcoming Patent Expirations and Market Entry
Upcoming patent expirations for major biologics like Keytruda and Eylea will trigger a wave of biosimilars, cutting costs and reshaping healthcare. Learn how these complex drugs differ from generics, who's developing them, and what it means for patients and providers.